VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 03/13/12 -- biOasis Technologies Inc. (TSX VENTURE:BTI) today announces positive test results from its Transcend therapeutic BT2111 development program directed towards the delivery of the therapeutic monoclonal antibody Herceptin® to the brain. An ADCC (antibody dependent cell-mediated cytotoxicity) assay showed that BT2111 conjugates retained Fc receptor binding activity and mediated human immune cell killing of HER2+ breast cancer cell line. The ADCC assay is used to measure the human immune system activity directed against Herceptin® bound to HER2+ cancer cells and is considered a good predictor of anti cancer activity. This positive ADCC activity complements previous results, obtained by the British Columbia Cancer Agency, which showed that BT2111 is able to bind to HER2+ cancer cells and kill them.
"The BT2111-Herceptin® program is advancing exceptionally well," said Rob Hutchison, CEO. "Herceptin® is known to have two types of activity against HER2+ breast cancer cells. We showed through the work performed at the British Columbia Cancer Agency that BT2111 was very effective in killing HER2+ cancer cells directly through HER2+ binding. Now, the ADCC assay confirms that the BT2111 conjugate functions to induce cell mediated cytotoxic activity against HER2+ cancer cells by facilitating the binding of human natural killer cells to HER2+ breast cancer cells. The ADCC assay results provides us with further confidence to advance the BT2111 program."
(i)Herceptin® is the registered trademark of Genentech, Inc.
ABOUT TRANSCEND & BT2111
biOasis is developing a proprietary vector for the transport of therapeutic and imaging agents across the blood-brain barrier - Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation of Transcend to a range of small molecule and large molecule biologic therapeutics, including monoclonal antibodies.